{"url_path":"/sec/brtx/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1505497/0001493152-26-023126-index.html","accession_number":"0001493152-26-023126","cik":"0001505497","ticker":"BRTX","issuer_name":"BioRestorative Therapies, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1505497/0001493152-26-023126-index.html","primary_entity_key":"0001505497","primary_entity_name":"BioRestorative Therapies, Inc."},"word_count":264,"has_tables":true,"body_markdown":"**Item\n6. Exhibits**\n\n \n\n \n \n \n \n**Incorporated\nby Reference**\n\n**Exhibit**\n\n**Number**\n\n \n**Exhibit\nDescription**\n \n**Form**\n \n**Exhibit**\n \n**Filing\nDate**\n\n3.1\n \n[Amended and Restated Articles of Incorporation](https://www.sec.gov/Archives/edgar/data/1505497/000102177123000002/ex3_3.htm)\n \n8-K\n \n3.3\n \n1/5/2023\n\n3.2\n \n[Bylaws](https://www.sec.gov/Archives/edgar/data/1505497/000102177123000002/ex3_5.htm)\n \n8-K\n \n3.5\n \n1/5/2023\n\n4.1\n \n[Form of Common Stock Warrant](https://www.sec.gov/Archives/edgar/data/1505497/000149315226005827/ex4-2.htm)\n \nS-1\n \n4.2\n \n2/9/2026\n\n4.2\n \n[Form of Placement Agent Warrant](https://www.sec.gov/Archives/edgar/data/1505497/000149315226005827/ex4-4.htm)\n \nS-1\n \n4.4\n \n2/9/2026\n\n10.1\n \n[Form of Securities Purchase Agreement, dated February 11, 2026, by and between BioRestorative Therapies, Inc. and the purchasers thereto](https://www.sec.gov/Archives/edgar/data/1505497/000149315226005827/ex10-50.htm)\n \nS-1\n \n10.50\n \n2/9/2026\n\n10.2\n \n[Placement Agency Agreement, dated February 11, 2026, by and between BioRestorative Therapies, Inc. and Rodman & Renshaw LLC](https://www.sec.gov/Archives/edgar/data/1505497/000149315226006837/ex10-2.htm)\n \n8-K\n \n10.2\n \n2/13/2026\n\n31.1*\n \n[Certification of Principal Executive Officer](ex31-1.htm)\n \n \n \n \n \n \n\n31.2*\n \n[Certification of Principal Financial Officer](ex31-2.htm)\n \n \n \n \n \n \n\n32.1**\n \n[Section 1350 Certification of Principal Executive Officer and Principal Financial Officer](ex32-1.htm)\n \n \n \n \n \n \n\n101.INS\n \nInline\nXBRL Instance Document\n \n \n \n \n \n \n\n101.SCH\n \nInline\nXBRL Taxonomy Extension Schema Document\n \n \n \n \n \n \n\n101.CAL\n \nInline\nXBRL Taxonomy Extension Calculation Linkbase Document\n \n \n \n \n \n \n\n101.DEF\n \nInline\nXBRL Taxonomy Extension Definition Linkbase Document\n \n \n \n \n \n \n\n101.LAB\n \nInline\nXBRL Taxonomy Extension Label Linkbase Document\n \n \n \n \n \n \n\n101.PRE\n \nInline\nXBRL Taxonomy Extension Presentation Linkbase Document\n \n \n \n \n \n \n\n104\n \nCover\nPage Interactive Date File (embedded within the Inline XBRL document)\n \n \n \n \n \n \n\n \n\n***\n*Filed\nherewith.*\n\n****\n*In\naccordance with SEC Release 33-8238, Exhibit 32.1 is being furnished and not filed.*\n\n \n\n27\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned, thereunto duly authorized.\n\n \n\n**BIORESTORATIVE\nTHERAPIES, INC.**\n \n\n \n \n \n\nBy:\n*/s/\nLance Alstodt*\n \n\n \nLance\nAlstodt\n \n\n \nChief\nExecutive Officer, President, and Chairman of the Board\n \n\n \n(Principal\nExecutive Officer)\n \n\nDate:\nMay\n14, 2026\n \n\n \n \n \n\nBy:\n*/s/\nRobert E. Kristal*\n \n\n \nRobert\nE. Kristal\n \n\n \nChief\nFinancial Officer\n \n\n \n(Principal\nFinancial Officer)\n \n\nDate:\nMay\n14, 2026\n \n\n \n\n28"}